People · Operator

Thomas O'Lenic

Named in public records as an officer, director or promoter · active 2024–2025 · Other Technology

1
Companies
2
Filings
$60.5M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
RedShift BioAnalytics, Inc.Other TechnologySeries B$60.5M$31.7M2024
Operator network

Thomas O'Lenic at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Bryson Hollimon · 4 companies · 1 sharedBryson HollimonFrank Smith · 4 companies · 1 sharedFrank SmithWilliam Cadogan · 3 companies · 1 sharedWilliam CadoganAmol Chaubal · 2 companies · 1 sharedAmol ChaubalCharles Purtell · 2 companies · 1 sharedCharles PurtellDon Bossi · 2 companies · 1 sharedDon BossiPaul Tardif · 2 companies · 1 sharedPaul TardifBryson Holliman · 1 companies · 1 sharedBryson HollimanCharles Marshall · 1 companies · 1 sharedCharles MarshallEugene Ma · 1 companies · 1 sharedEugene MaJulien Bradley · 1 companies · 1 sharedJulien BradleyMark Cafazzo · 1 companies · 1 sharedMark CafazzoRob Carson · 1 companies · 1 sharedRob CarsonSusan Holleran · 1 companies · 1 sharedSusan HolleranWouter Meuleman · 1 companies · 1 sharedWouter MeulemanRedShift BioAnalytics, Inc. · $60.5M raisedRedShift BioAnalytics…Thomas O'LenicTO
Thomas O'Lenic Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Thomas O'Lenic on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Bryson Hollimon14
Frank Smith14
William Cadogan13
Amol Chaubal12
Don Bossi12
Charles Purtell12
Paul Tardif12
Susan Holleran11
Wouter Meuleman11
Mark Cafazzo11
Bryson Holliman11
Julien Bradley11
Eugene Ma11
Rob Carson11
Charles Marshall11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.